October 29, 2026

Robert F. Kennedy Jr. Addresses Access to Unapproved Peptide Drugs

Health and Human Services Secretary Robert F. Kennedy Jr. is taking action to potentially broaden access to certain peptides promoted for health and wellness benefits. In a draft policy released on Wednesday, Kennedy signaled that compounding pharmacies may prepare six specific peptides—BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500—despite their lack of FDA approval.

According to Kennedy, allowing regulated compounding of these substances can offer patients a more controlled and safer alternative to existing options. Compounding pharmacies work by mixing specific ingredients to create tailored medications for patients’ individual needs. Though the peptides in Kennedy’s policy lack FDA approval, they are often promoted with health benefit claims.

The Department of Health and Human Services stated it would not intervene against licensed pharmacies or physicians compounding drug products with peptides not included in FDA-approved products. While many peptides like insulin have established safety and effectiveness approvals, these six remain under review.

An advisory panel recommended the use of these peptides in compounding in July, despite contradicting FDA scientists who expressed concerns about the lack of safety and effectiveness evidence. Kennedy referred to the panel’s recommendation to support his policy, emphasizing the importance of patient choice and safety.

A spokesperson for the HHS stated that pharmacies are expected to perform quality testing and safety reporting, ensuring that patients receive the necessary information about these peptide drugs. The policy, however, does not confer FDA approval or establish clinical safety. It insists on patient-specific prescriptions, traceable ingredients, and diligent safety monitoring.

The draft policy specifies the need for FDA-registered ingredient sources, laboratory certification for raw materials, and serious side effect reporting.

Recent investigations by CBS News revealed concerns surrounding the sale of unregulated peptide drugs. Tests conducted on samples purchased from a Brooklyn bodega showed inconsistencies, with some products like retatrutide found lacking the declared peptides.

Kennedy’s policy will be open for public commentary starting Friday and closing on November 13. It will remain in effect until the FDA formulates a definitive rule on compounded peptides, though no proposal has yet been advanced.

This report includes contributions from Dr. Céline Gounder, Adam Yamaguchi, and Kerry Breen.

TAGS: